204 related articles for article (PubMed ID: 20011514)
21. Kv7/KCNQ/M-channels in rat glutamatergic hippocampal axons and their role in regulation of excitability and transmitter release.
Vervaeke K; Gu N; Agdestein C; Hu H; Storm JF
J Physiol; 2006 Oct; 576(Pt 1):235-56. PubMed ID: 16840518
[TBL] [Abstract][Full Text] [Related]
22. Somatodendritic Kv7/KCNQ/M channels control interspike interval in hippocampal interneurons.
Lawrence JJ; Saraga F; Churchill JF; Statland JM; Travis KE; Skinner FK; McBain CJ
J Neurosci; 2006 Nov; 26(47):12325-38. PubMed ID: 17122058
[TBL] [Abstract][Full Text] [Related]
23. The Sensorless Pore Module of Voltage-gated K+ Channel Family 7 Embodies the Target Site for the Anticonvulsant Retigabine.
Syeda R; Santos JS; Montal M
J Biol Chem; 2016 Feb; 291(6):2931-7. PubMed ID: 26627826
[TBL] [Abstract][Full Text] [Related]
24. The pan-Kv7 (KCNQ) Channel Opener Retigabine Inhibits Striatal Excitability by Direct Action on Striatal Neurons In Vivo.
Hansen HH; Weikop P; Mikkelsen MD; Rode F; Mikkelsen JD
Basic Clin Pharmacol Toxicol; 2017 Jan; 120(1):46-51. PubMed ID: 27377794
[TBL] [Abstract][Full Text] [Related]
25. Activation of Kv7 Potassium Channels Inhibits Intracellular Ca
Ambrosino P; Soldovieri MV; Di Zazzo E; Paventi G; Iannotti FA; Mosca I; Miceli F; Franco C; Canzoniero LMT; Taglialatela M
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31487785
[TBL] [Abstract][Full Text] [Related]
26. K+ channels as potential targets for the treatment of gastrointestinal motor disorders.
Currò D
Eur J Pharmacol; 2014 Jun; 733():97-101. PubMed ID: 24726846
[TBL] [Abstract][Full Text] [Related]
27. Expression and motor functional roles of voltage-dependent type 7 K(+) channels in the human taenia coli.
Adduci A; Martire M; Taglialatela M; Arena V; Rizzo G; Coco C; Currò D
Eur J Pharmacol; 2013 Dec; 721(1-3):12-20. PubMed ID: 24120659
[TBL] [Abstract][Full Text] [Related]
28. Functional analysis of potassium channels in Kv7.2 G271V mutant causing early onset familial epilepsy.
Wang J; Li Y; Hui Z; Cao M; Shi R; Zhang W; Geng L; Zhou X
Brain Res; 2015 Aug; 1616():112-22. PubMed ID: 25960349
[TBL] [Abstract][Full Text] [Related]
29. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
Main MJ; Cryan JE; Dupere JR; Cox B; Clare JJ; Burbidge SA
Mol Pharmacol; 2000 Aug; 58(2):253-62. PubMed ID: 10908292
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and structure-activity relationship of acrylamides as KCNQ2 potassium channel openers.
Wu YJ; He H; Sun LQ; L'Heureux A; Chen J; Dextraze P; Starrett JE; Boissard CG; Gribkoff VK; Natale J; Dworetzky SI
J Med Chem; 2004 May; 47(11):2887-96. PubMed ID: 15139767
[TBL] [Abstract][Full Text] [Related]
31. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate.
Wuttke TV; Seebohm G; Bail S; Maljevic S; Lerche H
Mol Pharmacol; 2005 Apr; 67(4):1009-17. PubMed ID: 15662042
[TBL] [Abstract][Full Text] [Related]
32. Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
Kalappa BI; Soh H; Duignan KM; Furuya T; Edwards S; Tzingounis AV; Tzounopoulos T
J Neurosci; 2015 Jun; 35(23):8829-42. PubMed ID: 26063916
[TBL] [Abstract][Full Text] [Related]
33. Expression and function of Kv7.4 channels in rat cardiac mitochondria: possible targets for cardioprotection.
Testai L; Barrese V; Soldovieri MV; Ambrosino P; Martelli A; Vinciguerra I; Miceli F; Greenwood IA; Curtis MJ; Breschi MC; Sisalli MJ; Scorziello A; Canduela MJ; Grandes P; Calderone V; Taglialatela M
Cardiovasc Res; 2016 May; 110(1):40-50. PubMed ID: 26718475
[TBL] [Abstract][Full Text] [Related]
34. Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions.
Gao Z; Zhang T; Wu M; Xiong Q; Sun H; Zhang Y; Zu L; Wang W; Li M
J Biol Chem; 2010 Sep; 285(36):28322-32. PubMed ID: 20584905
[TBL] [Abstract][Full Text] [Related]
35. KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.
Zhang D; Thimmapaya R; Zhang XF; Anderson DJ; Baranowski JL; Scanio M; Perez-Medrano A; Peddi S; Wang Z; Patel JR; DeGoey DA; Gopalakrishnan M; Honore P; Yao BB; Surowy CS
J Neurosci Methods; 2011 Aug; 200(1):54-62. PubMed ID: 21723881
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and Evaluation of Potent KCNQ2/3-Specific Channel Activators.
Kumar M; Reed N; Liu R; Aizenman E; Wipf P; Tzounopoulos T
Mol Pharmacol; 2016 Jun; 89(6):667-77. PubMed ID: 27005699
[TBL] [Abstract][Full Text] [Related]
37. Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips.
Zagorchev P; Apostolova E; Kokova V; Peychev L
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):439-46. PubMed ID: 26815201
[TBL] [Abstract][Full Text] [Related]
38. Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator.
Perry M; Sachse FB; Sanguinetti MC
Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13827-32. PubMed ID: 17693551
[TBL] [Abstract][Full Text] [Related]
39. Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels.
Lange W; Geissendörfer J; Schenzer A; Grötzinger J; Seebohm G; Friedrich T; Schwake M
Mol Pharmacol; 2009 Feb; 75(2):272-80. PubMed ID: 19015229
[TBL] [Abstract][Full Text] [Related]
40. KV7 channelopathies.
Maljevic S; Wuttke TV; Seebohm G; Lerche H
Pflugers Arch; 2010 Jul; 460(2):277-88. PubMed ID: 20401729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
